Ország: Ausztrália
Nyelv: angol
Forrás: Department of Health (Therapeutic Goods Administration)
rosuvastatin calcium, Quantity: 41.583 mg
ORGANON PHARMA PTY LTD
Rosuvastatin calcium
Tablet, film coated
Excipient Ingredients: microcrystalline cellulose; hypromellose; mannitol; maize starch; sodium stearylfumarate; macrogol 6000; purified talc; silicon dioxide; lactose; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; iron oxide red
Oral
30 tablets
(S4) Prescription Only Medicine
MSD ROSUVASTATIN is indicated as an adjunct to diet when the response to diet and exercise is inadequate. Prevention of Cardiovascular Events: MSD ROSUVASTATIN is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease). MSD ROSUVASTATIN is indicated to:,? Reduce the risk of nonfatal myocardial infarction ? Reduce the risk of nonfatal stroke ? Reduce the risk of coronary artery revascularisation procedures,In patients with hypercholesterolaemia: MSD ROSUVASTATIN is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). Prior to initiating therapy with MSD ROSUVASTATIN, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.
Visual Identification: Brown, round, film coated tablets with "RSV 40" debossed on one side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2012-03-16